British Heart Journal最新文献_第8页

Foreword: Her Royal Highness The Princess Royal 前言:公主殿下

British Heart Journal Pub Date : 2022-04-21 DOI: 10.1136/heartjnl-2022-BCS-foreword

引用次数: 0

The Scottish contribution: the importance of the National Cardiac Societies and the Royal Colleges and their 100-year association with BCS 苏格兰的贡献:国家心脏学会和皇家学院的重要性，以及他们与BCS的百年合作

British Heart Journal Pub Date : 2022-04-21 DOI: 10.1136/heartjnl-2021-320142

F. Dunn, A. R. Lorimer

引用次数: 0

Changing concepts in heart muscle disease: the evolving understanding of hypertrophic cardiomyopathy 心肌疾病概念的变化:对肥厚性心肌病的认识的演变

British Heart Journal Pub Date : 2022-04-21 DOI: 10.1136/heartjnl-2021-320145

W. Moody, P. Elliott

{"title":"Changing concepts in heart muscle disease: the evolving understanding of hypertrophic cardiomyopathy","authors":"W. Moody, P. Elliott","doi":"10.1136/heartjnl-2021-320145","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320145","url":null,"abstract":"Sixty years ago, hypertrophic cardiomyopathy (HCM) was considered a rare lethal disease that affected predominantly young adults and for which there were few treatment options. Today, it is recognised to be a relatively common disorder that presents throughout the life course with a heterogeneous clinical phenotype that can be managed effectively in the majority of individuals. A greater awareness of the condition and less reluctance from healthcare practitioners to make the diagnosis, coupled with improvements in cardiac imaging, including greater use of artificial intelligence and improved yields from screening efforts, have all helped facilitate a more precise and timely diagnosis. This enhanced ability to diagnose HCM early is being paired with innovations in treatment, which means that the majority of patients receiving a contemporary diagnosis of HCM can anticipate a normal life expectancy and expect to maintain a good functional status and quality of life. Indeed, with increasing translation of molecular genetics from bench to bedside associated with a growing number of randomised clinical trials of novel therapies aimed at ameliorating or perhaps even preventing the disease, the next chapter in the story for HCM will provide much excitement and more importantly, offer much anticipated reward for our patients.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"768 - 773"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46342188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

The British Cardiovascular Society and clinical studies in ischaemic heart disease: from RITA to ORBITA, and beyond 英国心血管学会与缺血性心脏病的临床研究：从RITA到ORBITA及其他

British Heart Journal Pub Date : 2022-04-21 DOI: 10.1136/heartjnl-2021-320150

R. Al-Lamee, Louise Aubiniere-Robb, C. Berry

引用次数: 0

History of the British Cardiovascular Society 英国心血管学会的历史

British Heart Journal Pub Date : 2022-04-21 DOI: 10.1136/heartjnl-2021-320139

C. Coats

引用次数: 2

Heart valve disease: a journey of discovery 心脏瓣膜疾病:一个发现之旅

British Heart Journal Pub Date : 2022-04-21 DOI: 10.1136/heartjnl-2021-320146

L. Dobson, B. Prendergast

{"title":"Heart valve disease: a journey of discovery","authors":"L. Dobson, B. Prendergast","doi":"10.1136/heartjnl-2021-320146","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320146","url":null,"abstract":"In the centenary year of the British Cardiovascular Society (BCS), this review article outlines the influence of UK cardiologists and surgeons on the field of heart valve disease, many of whom can rightly claim ‘world firsts’ in the field. From the description of endocarditis as we know it today at the turn of the 20th century, to the first mitral valvotomy, heart valve replacement and invention of the Ross procedure. These advances have transformed the outlook of patients with symptomatic valve disease from palliation and certain death to curative treatment and near normal life expectancy. Transcatheter aortic valve implantation (TAVI) was adopted early in the UK, and thanks to the comprehensive national database, the UK TAVI registry is one of the world’s largest, contributing real-world patient data to inform clinical practice. The more recent concepts of ‘Heart Valve Centres of Excellence’ and specialist valve clinics have been developed by the BCS-affiliated British Heart Valve Society which continues to drive improved standards for patients with heart valve disease. The next 100 years will no doubt be equally thrilling in terms of innovation for heart valve disease, with artificial intelligence, transcatheter therapies and cutting-edge technology continuing to improve patient care and clinical outcomes.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"774 - 779"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42333143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Transcatheter aortic valve replacement: a gatekeeper for improving global disparities in patients with severe aortic stenosis 经导管主动脉瓣置换术:改善严重主动脉瓣狭窄患者全球差异的看门人

British Heart Journal Pub Date : 2022-04-13 DOI: 10.1136/heartjnl-2022-320992

M. Saji, M. Nanasato

引用次数: 1

British Heart Journal Pub Date : 2022-04-13 DOI: 10.1136/heartjnl-2021-320684

S. Marschner, A. von Huben, S. Zaman, H. Reynolds, V. W. Lee, P. Choudhary, L. Mehta, C. Chow

{"title":"Pregnancy-related cardiovascular conditions and outcomes in a United States Medicaid population","authors":"S. Marschner, A. von Huben, S. Zaman, H. Reynolds, V. W. Lee, P. Choudhary, L. Mehta, C. Chow","doi":"10.1136/heartjnl-2021-320684","DOIUrl":"https://doi.org/10.1136/heartjnl-2021-320684","url":null,"abstract":"Objective This study aims to examine the incidence of pregnancy-related cardiometabolic conditions and severe cardiovascular outcomes, and their relationship in US Medicaid-funded women. Methods Medicaid is a government-sponsored health insurance programme for low-income families in the USA. We report the incidence of pregnancy-related cardiometabolic conditions (hypertensive disorders and diabetes in, or complicated by, pregnancy) and severe cardiovascular outcomes (myocardial infarction, stroke, acute heart failure, cardiomyopathy, cardiac arrest, ventricular fibrillation, ventricular tachycardia, aortic dissection/aneurysm and peripheral vascular disease) among Medicaid-funded women with a birth (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code O80 or O82) over the period January 2015–June 2019, from the states of Georgia, Ohio and Indiana. In this cross-sectional cohort, we examined the relationship between pregnancy-related cardiometabolic conditions and severe cardiovascular outcomes from pregnancy through to 60 days after birth using multivariable models. Results Among 74 510 women, mean age 26.4 years (SD 5.5), the incidence per 1000 births of pregnancy-related cardiometabolic conditions was 224.3 (95% CI 221.3 to 227.3). The incidence per 1000 births of severe cardiovascular conditions was 10.8 (95% CI 10.1 to 11.6). Women with pregnancy-related cardiometabolic conditions were at greater risk of having a severe cardiovascular condition with an age-adjusted OR of 3.1 (95% CI 2.7 to 3.5). Conclusion This US cohort of Medicaid-funded women have a high incidence of severe cardiovascular conditions during pregnancy. Cardiometabolic conditions of pregnancy conferred threefold higher odds of severe cardiovascular outcomes.","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1524 - 1529"},"PeriodicalIF":0.0,"publicationDate":"2022-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47124949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Coronary vasospasm and future percutaneous coronary intervention: relax 冠状动脉血管痉挛与未来经皮冠状动脉介入治疗：放松

British Heart Journal Pub Date : 2022-04-12 DOI: 10.1136/heartjnl-2022-320974

M. McDermott, R. Bing

{"title":"Coronary vasospasm and future percutaneous coronary intervention: relax","authors":"M. McDermott, R. Bing","doi":"10.1136/heartjnl-2022-320974","DOIUrl":"https://doi.org/10.1136/heartjnl-2022-320974","url":null,"abstract":"A clinical diagnosis of suspected angina that is accompanied by non- obstructive epicardial coronary artery disease is not uncommon, as evidenced by results from contemporary registries and trials of anatomical testing in chest pain. The basket labelled as angina with non-obstructive coronary artery disease (ANOCA—the clinical syndrome that may or may not accompany ischaemia with non- obstructive coronary artery disease (INOCA)) contains heterogeneous patho-physiological entities which vary in clinical presentation and adjunctive investigation findings. 1 One distinct entry in this field is vasospastic angina, a dynamic phenomenon with characteristic symptoms that differ from those induced by fixed epicardial coronary artery stenoses. Although the seminal case series which provided the eponymous nomen-clature for this clinical syndrome was published well before many (probably most) readers of Heart were born, attempts to codify and standardise defini-tions for vasospastic angina have only recently been promulgated. 2 The syndrome is seen in only a small propor-tion of patients with chest pain, with correspondingly limited sections in current guidelines. 3 4 The diagnostic process can be difficult and the clinical course uncertain. The latter is salient, events. 5","PeriodicalId":9311,"journal":{"name":"British Heart Journal","volume":"108 1","pages":"1253 - 1254"},"PeriodicalIF":0.0,"publicationDate":"2022-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44595615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Cardiac resynchronisation therapy with or without a defibrillator: individualising device prescription 心脏再同步治疗有或没有除颤器:个体化设备处方

British Heart Journal Pub Date : 2022-04-11 DOI: 10.1136/heartjnl-2022-320909

S. Straw, W. Mullens, K. Witte

引用次数: 2